U.S. Food and Drug Administration Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Lynparza® (olaparib) in Combination with Abiraterone for Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Foundation Medicine’s tissue and liquid biopsy tests can now be used to identify more patients who could benefit from Lynparza in combination with abiraterone September 03, 2024 01:00 PM Eastern...